semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-65.0,  LAD1 Age 12-65 years Molecularly and cellularly confirmed LAD1 with inflammatory lesions Willing to allow storage of biological samples for future research Willing to allow genetic testing of blood samples Able to provide informed consent Participants who can get pregnant or impregnate a partner must agree to use adequate contraception when engaging in sexual activities that can result in pregnancy. Adequate contraception must be used consistently starting at screening and lasting through the final study visit. Appropriate forms of contraception the following: 1. Intrauterine device or equivalent. 2. Hormonal contraceptive (eg, consistent, timely, and continuous use of contraceptive pill, patch, ring, implant, or injection) that has reached full efficacy before dosing. 3. A double barrier method (eg, male/female condom, cap, or diaphragm plus spermicide). 4. Be in a stable, long-term monogamous relationship, per assessment of the principal investigator (PI), with a partner who does not pose any potential pregnancy risk, eg, has undergone a vasectomy at least 6 months before the first dose of study agent or is of the same sex as the participant. 5. Have had a hysterectomy and/or a bilateral tubal ligation or both ovaries removed  History of malignancy (except for basal cell carcinoma) within the previous 5 years Infected with HIV Active uncontrolled bacterial, viral, or fungal infection Active or chronic viral hepatitis Active or latent untreated tuberculosis Received Bacillus Calmette-Guerin vaccine within the last year Received live attenuated vaccines within 15 weeks before the first dose Allergy to any component of the ustekinumab formulation Pregnant or breastfeeding Any condition that, in the opinion of the investigator, contraindicates participation in this study
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 0.0-18.0,  Asthma Pediatric ALL Chief complaint consistent with asthma exacerbation Previous diagnosis of asthma by a physician OR one major in the Asthma Predictive Index (API) with two prior episodes of wheezing in the past year Major in the API: parent with asthma, patient with eczema, evidence of sensitization to allergens in the air Received oral corticosteroids as part of treatment during this visit for acute asthma exacerbation Deemed well enough after interventions to be discharged by the treating physician If <5 years of age, possession of nebulizer machine at home  Received asthma controller medications within four weeks prior to presentation Allergy to intervention asthma controller medications
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 40.0-130.0,  Chronic Obstructive Pulmonary Disease Patients will only be included in the study if they meet all of the following 1. Male or female patients aged 40 years or older. 2. Patient diagnosed with COPD for 1 year or more. 3. Patient presenting at least one spirometry with COPD FEV1/FVC fixed ratio &lt;0.70 post BD, in the last 12 months. 4. Patient is a current smoker or an ex-smoker with a smoking history of ≥ 10 pack- years. 5. Stable patients, as stated in medical records or patient reports during visit, defined as: without treatment due to exacerbation at study visit or within the previous 2 months, and without changes in maintenance COPD treatment regimen over the preceding 2 months (avoid first-time patient from participating in the study). 6. Patients must be able and willing to read and understand written instructions, and understand and complete the questionnaires required by the protocol. 7. After receiving full explanation, patients must have signed an informed consent document indicating that they understand the purpose of and the procedures required for the study and are willing to participate in the study  Patients who meet any of the following will not be eligible to participate in the study: 1. Patient with a diagnosis of sleep apnea syndrome or other chronic respiratory disease different from chronic obstructive diseases. 2. An acute or chronic condition that, in the investigator's opinion, would limit patient's ability to complete the questionnaires or participate in this study
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 65.0-130.0,  Asthma COPD Patients with a diagnosis of COPD or Asthma, medicated with any kind of inhaler device (pressurized Metered Dose Inhaler (pMDI) with or without Spacer, Dry Powder Inhaler (DPI) or Soft Mist), aged ≥65 years and being a regular user of primary health care services (defined as having at least one consultation performed in the last two years with his/her own Family Doctor). In order to minimize diagnostic inaccuracy, Asthma and COPD diagnosis will be reviewed in every participant at baseline prior to enrolment and according to GINA and GOLD strategies  Severe or acute illness (such as unstable cardiovascular status, unstable angina, recent myocardial infarction (within one month) or pulmonary embolism, haemoptysis of unknown origin, recent pneumothorax (within one month), recent thoracic, abdominal or eye surgery (within one month), acute nausea or vomiting, severe respiratory distress, dementia). Patients with intermittent asthma, as well as COPD patients with mild obstruction (GOLD class I) will be excluded, since these patients do not need to take inhaler medication on a daily basis, and tend to have a low frequency of disease exacerbations
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 5.0-18.0,  Asthma Diagnosed by asthma specialists, the age of onset was under 10 years old  Children with cancer, major immunological diseases, such as systemic lupus erythematosus (SLE) or Henoch-Schonlein purpura (HSP), rare hereditary diseases, or under severe infection Children who received ICS or oral steroid in recent 4 weeks
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 15.0-999.0,  Mental Disorder years patient or older presenting mental suffering or a frequent or severe mental disorder having consulted his GP who ask for psychiatric consultation having given its consent for the use of its medico-administrative data affiliated with the general health insurance scheme of which the GP is from Haute Garonne and is voluntary to participate in the study Free, informed and written consent signed by the participant and the investigator (at the latest on the day of and before any examination required by the research) and by one of the parents for minor participants  Patient with ongoing psychiatric follow-up Patient unable to answer questionnaires (unable to read or write) Patients receiving a measure of legal protection
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 10.0-17.0,  Type 1 Diabetes Child aged from 10 to 17 and 8 months Child with a type 1 diabetes (inclusion within 96 hours following the diagnosis, except for patients admitted to intensive care for whom an additional 24-hour period is accepted for their inclusion). Diagnosis will be confirmed based on one of the classic diagnostic venous glycaemia above 2 g / l, presence of polyuropolydipsic syndrome, presence of weight loss, presence of ketonuria (equivalent to at least one cross in urine or> 0.5mmol / l in blood) Child with internet access and with a computer or a tablet in at least one of the two parents or legal representative(s) Informed consent signed by parents or legal representative(s) (only one parent possible) Beneficiary of a social security system  No internet access or no computer or no tablet at home available No French language proficiency of the infant or legal representative(s) Inability to understand the game's instructions Inability to understand or fill the consent
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Copd adult smoker suspected of COPD  unable to perform spirometry
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Atopic Asthma Aged ≥18 2. Able to understand and give written informed consent 3. Has a diagnosis of atopic asthma (based on at least one positive skin prick test and Methacholine PC20 ≤16 mg/ml) 4. FEV1 (forced expiratory volume at 1 second) ≥ 70% of predicted 5. Demonstrate a cough response to capsaicin  Subjects who are in a pollen season that affects their asthma 2. Subjects who bronchoconstrict by more than 10% at the end of the full dose capsaicin cough challenge (assess after visit 1) 3. Subjects who do not display evidence of airway hyper-responsiveness (PC20>16mg/ml) (assess after visit 1) 4. Symptoms of upper respiratory tract infection (URTI) in the last 1 month which have not resolved. 5. Lower respiratory tract infection or pneumonia in the last 6 weeks. 6. Current smoker or ex-smoker with ≥10 pack year smoking history and abstinence of ≤6 months 7. Asthma exacerbation in the previous month requiring an increase or start of an ICS (inhaled corticosteroids) or OCS (oral corticosteroids) 8. Any asthma medication with the exception of infrequent (less than twice weekly) short-acting beta-agonist. 9. Subjects who have changed asthma medication within the past 4 weeks prior to screening 10. A previous asthma exacerbation requiring Intensive Care Unit (ICU) admission. 11. Significant other primary pulmonary disorders in particularly; pulmonary embolism, pulmonary hypertension, interstitial lung disease, lung cancer, cystic fibrosis, emphysema or bronchiectasis. 12. Pregnancy or breast-feeding 13. Use of ACE (angiotensin converting enzyme) inhibitors 14. Any centrally acting medication which in the view of the investigator could alter the sensitivity of the cough reflex 15. History of psychiatric illness, drug or alcohol abuse which may interfere in the participation of the trial
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Hyperventilation Syndrome Hypocapnia Alkalosis, Respiratory Hyperventilation The patient must have reached the age of the civil majority (≥ 18 yo) 2. All patients refered to the Physiology department of Rouen University Hospital, France, for an hyperventilation test 3. The patient must be a member or beneficiary of a health insurance program 4. The patient must have given his / her free and informed consent and signed the consent  Sepsis 2. Hypercapnia (PaCO2 > 50mmHg) 3. Patient treated by long-term oxygen therapy 4. Subjects under judicial protection, or adults under any kind of guardianship or under judicial control 5. Pregnancy or breastfeeding women 6. Electrolytic unbalance 7. Hyperthyroidism 8. Neurological disease 9. Probability of drug-induced hyperventilation (progestagens , aspirin, beta agonists)
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 6.0-15.0,  Asthma Acute Asthma in Children Asthma Chronic Asthma Attack Physician-diagnosed mild or moderate persistent asthma 2. On controller therapy [inhaled corticosteroid (ICS), ICS + leukotriene receptor antagonist (LTRA), or ICS + long-acting beta agonist (LABA)] for at least the previous six months 3. At least one severe exacerbation requiring systemic corticosteroids in the previous year 4. Baseline FEV1 >/= 70% predicted for age, gender, and height according to published reference standards 5. Parental consent and the child's assent  Chronic obstructive respiratory disorder other than asthma (e.g., cystic fibrosis, primary ciliary dyskinesia) 2. Severe persistent asthma, as evidenced by any of the following hospitalizations severe exacerbations in the previous year on chronic oral corticosteroid therapy daily symptoms 3. Inability to perform acceptable spirometry 4. History of collapsed lung 5. History of syncope with forced exhalation 6. Not owning an iOS™ device (e.g., iPhone®, iPod®, or iPad®) 7. Lacking access to wireless local area networking (Wi-Fi™)
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 6.0-16.0,  Asthma in Children Have asthma which is partly controlled based on Global Initiative for Asthma (GINA) asthma control classification guideline and has Asthma Control Test (ACT) score ≥17 at point of recruitment Currently using fluticasone as the only regular inhaled corticosteroid therapy for asthma control with fluticasone dosage ≤ 250mcg/day for at least past 3 months Able to perform pulmonary function test Fulfil the TCM of "lung-spleen qi deficiency " type of asthma  Laboratory results for renal and liver functions outside of normal range Concomitant use of theophylline or montelukast Concomitantly or in the last 3 months taking TCM Pregnant or lactation Known allergic reactions to food such as peanut, seafood, egg and milk
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 6.0-17.0,  Asthma in Children Clinical diagnosis of asthma Fractional excretion of exhaled nitric oxide (FeNO) > 50 ppb OR a history of environmental allergies No emergency department or hospital visits for asthma in the past 3 months No systemic corticosteroids in the past 1 month Ability to consume a liquid drink of SCF or placebo Ability to return for a 4-6 week follow-up visit No special or unique diet as determined by PI/CO-Is  Cystic fibrosis Bronchiectasis Change in asthma medicines other than short acting bronchodilators planned over the next 4-6 weeks
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 1.0-15.0,  Asthma Asthmatic children aged 1-15 years old from Pediatric Allergy and Immunology division with hospitalized due to severe asthma exacerbation in a preceding year and without severe asthma exacerbation in a preceding year  Other serious systemic diseases, pregnant, lactation